[Form 4] Orchestra BioMed Holdings, Inc. Insider Trading Activity

Rhea-AI Filing Summary

Orchestra BioMed Holdings director Mack John Prosper was awarded 15,000 restricted stock units (RSUs) on 08/07/2025. Each RSU represents a contingent right to receive one share of common stock and the award shows a per-unit price of $0. The RSUs are scheduled to vest on the one-year anniversary of the grant, subject to the reporting persons continuous service through that date. After this award the reporting person beneficially owns 40,286 shares on a direct basis.

The Form 4 shows the transaction as an acquisition (code A) and was filed by one reporting person. No derivative securities or additional transactions are reported in this filing and no other material details are provided.

Positive

• Award of 15,000 RSUs to director reported, increasing direct beneficial ownership to 40,286 shares
• RSUs vest in one year subject to continuous service, with each RSU representing one share and showing a price of $0

Negative

• None.

Insights

Securities Analyst

TL;DR: Director Mack John Prosper received 15,000 RSUs that vest in one year, bringing direct beneficial ownership to 40,286 shares.

The filing documents an award of 15,000 RSUs granted on 08/07/2025, each representing a contingent right to one share with a reported price of $0. Vesting is conditioned on continuous service through the one-year anniversary. The Form 4 reports this as an acquisition and lists 40,286 shares beneficially owned following the transaction. There are no derivative holdings or other transactions disclosed. Based solely on the filings content, this is a discrete equity award disclosure without additional corporate or financing actions described.

Corporate Governance Expert

TL;DR: A director award of 15,000 RSUs is disclosed, vesting after one year; the filing reports the updated direct ownership total.

The statement explicitly describes the grant as an award of restricted stock units, each convertible into one share, vesting on a one-year schedule contingent on continued service. The filing shows acquisition code "A" and lists the reporting person as a director. The document does not disclose any accelerated vesting, transfer restrictions beyond the service condition, or related-party transactions. From a governance-disclosure perspective, the filing provides the standard, required details for an insider equity award but does not include additional governance actions or changes to board composition.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Mack John Prosper

(Last) (First) (Middle)

C/O ORCHESTRA BIOMED HOLDINGS, INC.

150 UNION SQUARE DRIVE

(Street)

NEW HOPE PA 18938

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Orchestra BioMed Holdings, Inc. [ OBIO ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
08/07/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock, par value $0.0001 per share ("Common Stock")	08/07/2025		A		15,000(1)	A	$0	40,286	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents an award of restricted stock units ("RSUs") awarded to the Reporting Person on August 7, 2025 (the "Grant Date"). Each RSU represents a contingent right to receive one share of Common Stock. The RSUs will vest on the one year anniversary of the Grant Date, subject to the Reporting Person's continuous service through such date.

	/s/ Andrew Taylor, Attorney-in-Fact	08/08/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What transaction did Orchestra BioMed (OBIO) disclose on this Form 4?

The Form 4 reports an award of 15,000 RSUs to director Mack John Prosper on 08/07/2025, reported as an acquisition (code A).

How many shares does the reporting person own after the transaction?

Following the reported award, the reporting person beneficially owns 40,286 shares on a direct basis.

What are the vesting terms for the RSUs reported by OBIO?

The RSUs will vest on the one-year anniversary of the grant date, contingent on the reporting person's continuous service through that date.

What is the conversion or price reported for the RSUs?

Each RSU represents a contingent right to one share and the filing lists a price of $0 for the awarded RSUs.

Did the Form 4 report any derivative securities or other transactions for OBIO?

No. The filing contains only the non-derivative RSU award and does not report any derivative securities or additional transactions.